Laman UtamaB1MR34 • BVMF
add
Biomarin Pharmaceutical Inc Bdr
Tutup sebelumnya
R$165.45
Julat tahun
R$165.45 - R$258.34
Permodalan pasaran
11.37B USD
Bilangan Purata
47.00
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Mac 2025info | Perubahan T/T |
|---|---|---|
Hasil | 745.14J | 14.84% |
Perbelanjaan pengendalian | 210.96J | -12.17% |
Pendapatan bersih | 185.69J | 109.43% |
Margin untung bersih | 24.92 | 82.43% |
Pendapatan bagi setiap syer | 1.13 | 59.15% |
EBITDA | 245.96J | 132.45% |
Kadar cukai berkesan | 22.01% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Mac 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 1.27B | 21.57% |
Jumlah aset | 7.15B | 3.99% |
Jumlah liabiliti | 1.35B | -24.76% |
Jumlah ekuiti | 5.79B | — |
Syer tertunggak | 191.78J | — |
Harga kepada buku | 5.48 | — |
Pulangan pada aset | 7.92% | — |
Pulangan pada modal | 8.82% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Mac 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | 185.69J | 109.43% |
Tunai daripada operasi | 174.39J | 271.28% |
Tunai daripada pelaburan | -28.24J | -98.36% |
Tunai daripada pembiayaan | -38.78J | 9.38% |
Perubahan bersih dalam tunai | 105.96J | 1,403.17% |
Aliran tunai bebas | 102.79J | 376.04% |
Perihal
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Diasaskan
Mac 1997
Ibu pejabat
Tapak web
Pekerja
3,040
